NCT03682796View on ClinicalTrials.gov

Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
LymphomaLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, Mantle-CellLymphoma, Marginal ZoneLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
Interventions
DRUG

TRPH-222

administered by IV, 21-day Cycle

Trial Locations (7)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

43219

Ohio State University Comprehensive Cancer Center, Columbus

85234

Banner MD Anderson, Gilbert

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Triphase Research and Development III Corp.

INDUSTRY

NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Biotech Hunter | Biotech Hunter